No abstract

progression (+0.31, 95%CI -1.61O-2.16) with following acceleration of GFR slope ) from CKD3 -5% of patients.Dialysis was started at eGFR 7AE3 ml/min/1.73m 2 in "slow" group (29% -urgent start), 6AE4 ml/min/1.73m 2 in "fast" group (53% -urgent start) and 5AE4 ml/min/1.73m 2 in "accelerated" group (59% -urgent start). The rate of renal replacement therapy over the 5-year observation period was 0.9%, 2.2%, 13.8% and 48.1%, respectively, for CKD stages 2, 3, 4, 5 while the mortality rate was 19.6%, 29.1%, 52.85 and 39.8% mainly for cardiovascular reasons. Thus, death was far more common than dialysis at all stages but CKD5, where it was comparable. Conclusions: The identifying of the modifiable factors linked to CKD progression gives the opportunity to improve comprehensive renoprotective therapy. The efforts to decrease mortality in CKD3-4 cohort should be focused on prevention and treatment of coronary artery disease, congestive heart failure, diabetes mellitus, phosphatemia and anemia